Treatment of Human Respiratory Syncytial Virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade®, PS-341) results in increased inflammation and mortality

Toxicology

Volumn 268, Issue 1-2, 2010, Pages 25-30

  Lupfer, Christopher ^a,b   Patton, Kristin M ^b   Pastey, Manoj K ^b  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

(1R) 3 Methyl 1 (2S) 1 oxo 3 phenyl 2 (pyrazinylcarbonyl)amino propyl amino butyl boronic acid; Antiviral; Bortezomib; Inflammation

Indexed keywords

BORTEZOMIB; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEASOME INHIBITOR; RANTES;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; VERO CELL; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; BORONIC ACIDS; CERCOPITHECUS AETHIOPS; CYTOKINES; ENZYME INHIBITORS; INFLAMMATION; MICE; MICE, INBRED BALB C; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VERO CELLS; VIRUS REPLICATION;

ANIMALIA; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDRANGEA RINGSPOT VIRUS; MUS;

EID: 73749083772     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2009.11.014     Document Type: Article

References (32)

1. Adams J., Palombella V.J., Sausville E.A., Johnson J., Destree A., Lazarus D.D., Maas J., Pien C.S., Prakash S., and Elliott P.J. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59 11 (1999) 2615-2622
2. Belay E.D., Bresee J.S., Holman R.C., Khan A.S., Shahriari A., and Schonberger L.B. Reye's syndrome in the United States from 1981 through 1997. N. Engl. J. Med. 340 18 (1999) 1377-1382
3. + T cells. Immunology 124 2 (2008) 234-246
4. Bitko V., Shulyayeva O., Mazumder B., Musiyenko A., Ramaswamy M., Look D.C., and Barik S. Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-{kappa}B-dependent, interferon-independent mechanism and facilitate virus growth. J. Virol. 81 4 (2007) 1786-1795
5. Brown H.J., McBride W.H., Zack J.A., and Sun R. Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir. Ther. 10 6 (2005) 745-751
6. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., St. George K., Epperson S., Brammer L., Klimov A.I., Bresee J.S., and Fry A.M.O.R.W.G. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. J. Am. Med. Assoc. 301 10 (2009) 1034-1041
7. Fiedler M.A., and Wernke-Dollries K. Incomplete regulation of NF-kappa B by Ikappa Balpha during respiratory syncytial virus infection in A549 cells. J. Virol. 73 5 (1999) 4502-4507
8. Fukayama M., Hino R., and Uozaki H. Epstein-Barr Virus and gastric carcinoma: virus-host interactions leading to carcinoma. Cancer Sci. 99 9 (2008) 1726-1733
9. Girard M.P., Cherian T., Pervikov Y., and Kieny M.P. A review of vaccine research and development: human acute respiratory infections. Vaccine 23 50 (2005) 5708-5724
10. Gotoh A., Ohyashiki K., Oshimi K., Usui N., Hotta T., Dan K., and Ikeda Y. Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung injury by bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology. Int. J. Hematol. 84 5 (2006) 406-412
11. Harty R.N., Brown M.E., McGettigan J.P., Wang G., Jayakar H.R., Huibregtse J.M., Whitt M.A., and Schnell M.J. Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction. J. Virol. 75 22 (2001) 10623-10629
12. Hideshima T., Richardson P., Chauhan D., Palombella V.J., Elliott P.J., Adams J., and Anderson K.C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61 7 (2001) 3071-3076
13. Kalogeris T.J., Laroux F.S., Cockrell A., Ichikawa H., Okayama N., Phifer T.J., Alexander J.S., and Grisham M.B. Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am. J. Physiol. Cell Physiol. 276 4 (1999) C856-C864
14. Kim S.J., Kim K., Kim B.S., Lee H.J., Kim H., Lee N.R., Nam S.H., Kwon J.H., Kim H.J., Sohn S.K., Won J.H., Lee J.H., Suh C., Yoon S.S., Kim I., Do Y.R., Lee W.S., Joo Y.D., and Shin H.J. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin. Lymph. Myeloma 8 4 (2008) 237-240
15. Martin-Serrano J. The role of ubiquitin in retroviral egress. Traffic 8 10 (2007) 1297-1303
16. Martin-Serrano J., Eastman S.W., Chung W., and Bieniasz P.D. HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. J. Cell Biol. 168 1 (2005) 89-101
17. Martin-Serrano J., Perez-Caballero D., and Bieniasz P.D. Context-dependent effects of L domains and ubiquitination on viral budding. J. Virol. 78 11 (2004) 5554-5563
18. Miyakoshi S., Kami M., Yuji K., Matsumura T., Takatoku M., Sasaki M., Narimatsu H., Fujii T., Kawabata M., Taniguchi S., Ozawa K., and Oshimi K. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107 9 (2006) 3492-3494
19. Mortenson M.M., Schlieman M.G., Virudachalam S., and Bold R.J. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line. Cancer Chemother. Pharmacol. 54 4 (2004) 343-353
20. Müller B., and Kräusslich H.-G. Antiviral Strategies (2009), Springer, Berlin/Heidelberg/New York, NY pp. 1-24
21. Nencioni A., Schwarzenberg K., Brauer K.M., Schmidt S.M., Ballestrero A., Grunebach F., and Brossart P. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 108 2 (2006) 551-558
22. Neznanov N., Dragunsky E.M., Chumakov K.M., Neznanova L., Wek R.C., Gudkov A.V., and Banerjee A.K. Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. PLoS ONE 3 4 (2008) e1887
23. Nucci M., and Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin. Infect. Dis. 49 8 (2009) 1211-1225
24. Onitilo A.A., Engel J., Olatosi B., and Fagbemi S. Community experience with bortezomib in patients with multiple myeloma. Am. J. Hematol. 82 7 (2007) 637-639
25. Pitini V., Arrigo C., Altavilla G., and Naro C. Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?. Leuk. Res. 31 7 (2007) 1027-1028
26. Richardson P.G., Xie W., Mitsiades C., Chanan-Khan A.A., Lonial S., Hassoun H., Avigan D.E., Oaklander A.L., Kuter D.J., Wen P.Y., Kesari S., Briemberg H.R., Schlossman R.L., Munshi N.C., Heffner L.T., Doss D., Esseltine D.L., Weller E., Anderson K.C., and Amato A.A. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 27 21 (2009) 3518-3525
27. Saito R., Li D., Suzuki Y., Sato I., Masaki H., Nishimura H., Kawashima T., Shirahige Y., Shimomura C., Asoh N., Degawa S., Ishikawa H., Sato M., Shobugawa Y., and Suzuki H. High prevalence of amantadine-resistance influenza A (H3N2) in six prefectures, Japan, in the 2005-2006 season. J. Med. Virol. 79 (2007) 1569-1576
28. Schmitt A.P., Leser G.P., Morita E., Sundquist W.I., and Lamb R.A. Evidence for a new viral late-domain core sequence, FPIV, necessary for budding of a paramyxovirus. J. Virol. 79 5 (2005) 2988-2997
29. Teicher B.A., Ara G., Herbst R., Palombella V.J., and Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. 5 9 (1999) 2638-2645
30. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., and Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. J. Am. Med. Assoc. 289 2 (2003) 179-186
31. Yokose N., Hirakawa T., and Inokuchi K. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib. Leuk. Res. 33 8 (2009) e106
32. Zappasodi P., Dore R., Castagnola C., Astori C., Varettoni M., Mangiacavalli S., Lazzarino M., and Corso A. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J. Clin. Oncol. 25 22 (2007) 3380-3381